BiotechTube
Home/Alector/Neil Berkley, M.S., M.B.A.
NB

Neil Berkley, M.S., M.B.A.

Chief Financial Officer and Chief Business Officer

Alector

Therapeutic Areas

Neurodegenerative DiseasesNeurologyImmunology

Alector Pipeline

DrugIndicationPhase
AL001 (Latozinemab)Frontotemporal Dementia with progranulin mutation (FTD-GRN)Phase 3
AL101 / GSK4527226Early Alzheimer's DiseasePhase 2
AL002Early Alzheimer's DiseasePhase 2
AL001FTD with C9orf72 mutation (FTD-C9orf72)Phase 2
AL101Parkinson's DiseasePreclinical
AL137-ABCAlzheimer's DiseasePreclinical
AL050-ABCParkinson's Disease, Gaucher Disease, Lewy Body DementiaPreclinical
AL064-ABC / ADP064-ABCAlzheimer's Disease, Frontotemporal DementiaResearch

Leadership Team at Alector

AR
Arnon Rosenthal, Ph.D.
Co-Founder, Chief Executive Officer, and Director
GS
Giacomo Salvadore, M.D.
Chief Medical Officer
View full Alector profile